.
.
.
.
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
- Gluten intolerance a significant risk factor
- Infectious disease of the uterus
- Absence of an individual specific disease